Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor conferences: TD Cowen 46th Annual ...
Tuesday, February 17, 2026 2 min read
Key Takeaway: Jazz Pharmaceuticals announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and the Barclays 28th Annual Global Healthcare Conference on March 12, 2026. The company plans to host audio webcasts of the events available on its investor website, with replays archived for 30 days. This engagement reflects Jazz's ongoing focus on innovation and patient-centered therapeutic solutions.
Market Sentiment Analysis
POSITIVE FACTORS
Participation in important investor conferences indicates business engagement.
Opportunity to share insights on innovative therapeutics and pipeline advancements.
Continued commitment to developing life-changing medicines for rare diseases.
Full Press Release Details
DUBLIN , Feb. 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company will participate in the following investor conferences:
TD Cowen 46 th Annual Health Care Conference on Tuesday, March 3, 2026
Barclays 28 th Annual Global Healthcare Conference on Thursday, March 12, 2026
An audio webcast of both fireside chats will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations . A replay of the webcasts will be archived on the website for 30 days.
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.